SAB Biotherapeutics

SABS · NASDAQ

$2.88+$0.28 (+10.77%)TodayMarket closed ·
Prev close $2.60

Who owns SABS

Largest institutional holders, from their latest 13F filings

The 10 largest institutions hold 62.6% of SABS’s shares.

  • Caligan Partners, LP10.4%
  • Vivo Capital, LLC9.5%
  • Perceptive Advisors LLC8.7%
  • Adage Capital Management, L.P.8.4%
  • Next 6 largest institutions25.6%
  • All other shareholders37.4%
Top institutional holders of SABS
HolderShares% of shares
Caligan Partners, LP7.97M10.42%
Vivo Capital, LLC7.30M9.55%
Perceptive Advisors LLC6.63M8.67%
Adage Capital Management, L.P.6.41M8.38%
RA Capital Management, LP4.40M5.76%
Balyasny Asset Management LP3.76M4.92%
Vanguard Capital Management, LLC2.97M3.89%
Commodore Capital LP2.87M3.75%
BlackRock Institutional Trust Company, N.A.2.84M3.71%
Millennium Management LLC2.75M3.60%

Largest mutual fund holders

Top mutual fund holders of SABS
HolderShares% of shares
Vanguard Total Stock Market Index Fund2.26M2.96%
iShares Russell 2000 ETF1.05M1.37%
Vanguard Extended Market Index Fund647.89K0.85%
Fidelity Small Cap Index Fund474.46K0.62%
iShares Russell 2000 Value ETF381.63K0.50%

Insider trades

Form 4 filings by officers, directors and large holders

Insiders made no open-market buys or sales of SABS in the last 6 months.

Latest SABS insider transactions
InsiderTypeSharesValue
Kropotova AlexandraTax withholding473—
Kropotova AlexandraTax withholding988—

Short interest

Settled Sep 30, 2026

Shares short
4.29M
Days to cover
4.99
% of shares outstanding
5.61%
Average daily volume
860.64K
Change since last report
+19.1%

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.